Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

TRANXENE CAP 3.75MG DIN 00264938

Status: Cancelled Post Market
Holder: ABBOTT LABORATORIES, LIMITED
Molecule: CLORAZEPATE DIPOTASSIUM

Health Canada record

Active ingredient(s)CLORAZEPATE DIPOTASSIUM 3.75 MG
Dosage formCapsule
RouteOral
ScheduleTARGETED SUBSTANCES (CDSA IV)
ClassHuman
ATCN05BA05 CLORAZEPATE POTASSIUM
Original market date31-Dec-1973
Current status date01-Aug-2003
SourceHealth Canada DPD

Establishment licence of the holder

Abbott Laboratories Co. — licence 3-002635, currently licensed, last inspection rating C (2024-09-23).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing CLORAZEPATE DIPOTASSIUM

DINProductCompanyFormStrengthStatus
00860689CLORAZEPATEAA PHARMA INCCapsuleCLORAZEPATE DIPOTASSIUM 3.75 MGMarketed
00860700CLORAZEPATEAA PHARMA INCCapsuleCLORAZEPATE DIPOTASSIUM 7.5 MGMarketed
00860697CLORAZEPATEAA PHARMA INCCapsuleCLORAZEPATE DIPOTASSIUM 15 MGMarketed
00628212NOVO-CLOPATE CAP 15MGNOVOPHARM LIMITEDCapsuleCLORAZEPATE DIPOTASSIUM 15 MGCancelled Post Market
00628190NOVO-CLOPATE CAP 3.75MGNOVOPHARM LIMITEDCapsuleCLORAZEPATE DIPOTASSIUM 3.75 MGCancelled Post Market
00628204NOVO-CLOPATE CAP 7.5MGNOVOPHARM LIMITEDCapsuleCLORAZEPATE DIPOTASSIUM 7.5 MGCancelled Post Market
00264911TRANXENE CAP 15MGABBOTT LABORATORIES, LIMITEDCapsuleCLORAZEPATE DIPOTASSIUM 15 MGCancelled Post Market
00264946TRANXENE CAP 7.5MGABBOTT LABORATORIES, LIMITEDCapsuleCLORAZEPATE DIPOTASSIUM 7.5 MGCancelled Post Market

International API supply for CLORAZEPATE DIPOTASSIUM

4 active FDA Drug Master Files.

Request a quote for TRANXENE CAP 3.75MG

How to read a Canadian DIN record